Renpeng Zhou

Dr. Renpeng Zhou


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 April 2023 in Journal of Craniofacial Surgery
Verified
Journal Article
Open access
XFXiujun Fu
Xiujun Fu
YCyin chuang
yin chuang
YLYimin Liang
Yimin Liang
RZRenpeng Zhou
Renpeng Zhou
DWDanru Wang
Danru Wang
CWChen Wang
Chen Wang
Background: Autologous costal cartilage has been used for augmentation rhinoplasty in Asia for many years. This study aimed to assess the effectiveness and safety of hybrid grafting of costal cartilage for dorsal augmentation, septal reconstruction, and tip augmentation for Asian patients. Methods: A surgical technique was introduced and patients having rhinoplasty using this technique from April 2020 to March 2021 were retrospectively studied. In this technique, costal cartilage was meticulously carved or diced and grafted in various ways mainly based on the anatomic characteristics of nasal skin and subcutaneous soft tissues as well as bone and cartilage framework. The surgical outcomes, patient satisfaction, and complications retrieved from the documented medical records were reviewed and analyzed. Results: Twenty-five patients having rhinoplasty with the proposed technique were followed up from 6 months to 12 months. As for cosmetic outcomes, 21 patients were graded as good, 3 patients were graded as fair, and only 1 patient was graded as poor. Those patients who were not graded as good had over-rotated tips, insufficient dorsal augmentation, or asymmetry of nostrils and soft tissue contracture. The overall patient satisfaction was as high as 96.0%. Local infection occurred in 1 patient and hematoma was not observed. Warping and visibility of costal cartilage were not observed in any patients. Slight displacement of diced cartilages was found in 2 patients near the radix 1 week postoperatively. Conclusions: Hybrid autologous costal cartilage grafts can be used for both tip refinement and dorsal augmentation for East Asian patients and achieve an outcome of a natural-looking nose with minimal complications. Level of Evidence: Level IV.

30 November 2023 in Materials Today Bio
Verified
Journal Article
Open access
YLYimin Liang
Yimin Liang
CWChunmeng Wang
Chunmeng Wang
SYShiyang Yu
Shiyang Yu
YFYujia Fan
Yujia Fan
YJYuhang Jiang
Yuhang Jiang
YSYangbai Sun
Yangbai Sun
Osteosarcoma (OS) is the third most common malignancy in adolescence. Currently, the treatments of OS confront great obstacles of tumor recurrence and critical bone defects after surgery, severely affecting the survival rates and living qualities of patients. Hence, it is urged to develop distinct biomaterials with both efficient tumor therapeutic and osteogenic functions. Although photothermal therapy (PTT) has aroused expanding interest, characterizing negligible invasiveness and high spatiotemporal adjustment, few studies discussed its drawbacks, such as thermal injury to adjacent normal tissue and exceeded laser power density, implying that focusing on sensitizing OS to PTT instead of simply elevating the laser power density may be a fresh way to enhance the PTT efficacy and attenuate the side/adverse effects. Herein, we successfully constructed 3D-printing silicene bioactive glass scaffolds with preferable PTT efficacy at the second near-infrared (NIR-II) biowindow and outstanding osteogenic biofunctions owing to the release of bioactive elements during degradation. Impressively, a histone demethylase inhibitor, IOX1, was introduced before PTT to sensitize OS to thermal therapy and minimize the side/adverse effects. This work offered a distinctive paradigm for optimizing the PTT efficacy of osteogenic scaffolds against OS with epigenetic modulation agents.

6 November 2023 in Experimental Dermatology
Verified
Journal Article
Closed access
QWQirui Wang
Qirui Wang
XHXingtai Huang
Xingtai Huang
SZSiyi Zeng
Siyi Zeng
RZRenpeng Zhou
Renpeng Zhou
DWDanru Wang
Danru Wang

20 June 2025 in Aesthetic Plastic Surgery
Verified
Journal Article
Closed access
PDF file
RLRuoshui Liu
Ruoshui Liu
DWDanru Wang
Danru Wang
RZRenpeng Zhou
Renpeng Zhou

1 January 2023 in Dermatologic Therapy
Verified
Journal Article
Open access
PDF file
YLYimin Liang
Yimin Liang
ADAngang Ding
Angang Ding
DLDongze Lv
Dongze Lv
DWDanru Wang
Danru Wang
RZRenpeng Zhou
Renpeng Zhou
Intralesional 5‐fluorouracil (5‐FU) and triamcinolone acetonide (TAC) injection is effective for the treatment of hypertrophic scar. The side effects of current that recommended 45 mg/ml (high‐dose) 5‐FU have been reported. However, no previous study has investigated the efficacy and safety of low‐dose (2.5 mg/ml) 5‐FU with 4 mg/ml TAC or medium‐dose (10 mg/ml) 5‐FU with 4 mg/ml TAC for treatment of hypertrophic scar. Herein, a retrospective comparative study was conducted. The records of 70 patients, treated with low‐dose (2.5 mg/ml) 5‐FU and 4 mg/ml TAC every 4 weeks (Group 1) or medium‐dose (10 mg/ml) 5‐FU and 4 mg/ml TAC every 4 weeks (Group 2), were analyzed. The Vancouver Scar Scale (VSS), vascularity, and thickness of hypertrophic scar at baseline and at 7th‐treatment (each group received 6 treatment sessions) were compared. The ultrasound showed the large vascular distribution in scar margins. Both groups gained clinical improvement in VSS, vascularity, and thickness. Group 2 (medium‐dose) exhibited significantly better improvement than Group 1 (low‐dose). However, the overall side effects rate was 11.4% in Group 1, significantly lower than 31.4% in Group 2. Scar margins were suggested to be target sites for injection. Medium‐dose (10 mg/ml) 5‐FU + 4 mg/ml TAC could effectively reduce the thickness of hypertrophic scar; however, the side effects rate was also higher in medium‐dose group than in low‐dose group.

9 December 2024 in Aesthetic Plastic Surgery
Verified
Journal Article
Closed access
PDF file
RZRenpeng Zhou
Renpeng Zhou
YZYi Zhang
Yi Zhang
DLDongze Lyu
Dongze Lyu
CWChen Wang
Chen Wang